Leerink raised the firm’s price target on Zymeworks (ZYME) to $40 from $37 and keeps an Outperform rating on the shares after the company announced a strategic transformation from a traditional biotech into a revenue-generating royalty aggregator. The firm reiterated its Outperform rating given current valuation and its belief that the full HERIZON GEA-01 presentation will be a favorable catalyst. Additionally, current zani royalties/milestones represents roughly $29 in the firm’s model, suggesting the stock is undervalued on zani fundamentals alone, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks price target raised to $25 from $17 at Wells Fargo
- Zymeworks price target raised to $40 from $30 at Stifel
- Zymeworks’ Promising Phase 3 Results Drive Buy Rating for HER2-Positive Cancer Treatment
- Zymeworks Appoints Scott Platshon as Acting CIO
- Zymeworks price target raised to $32 from $26 at H.C. Wainwright